Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
AssigneeNelson M. Karp
InventorNelson M. Karp
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RiNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Claims30
An immunogenic composition comprising, an HIV-1 MA polypeptide myristate binding site said polypeptide consisting of SEQ ID NO.:
- 1, and a pharmaceutically acceptable carrier, wherein said composition is capable of inducing a Th1 immune response to HIV-1.
A method of inducing a Th1 immune response in a host comprising, administering to said host an immunogenic composition comprising an HIV-1 MA polypeptide myristate binding site said polypeptide consisting of SEQ ID NO.:
- 1, and a pharmaceutically acceptable carrier, wherein said composition induces a Th1 anti-HIV immune response.
An immunogenic composition comprising, an HIV-1 MA polypeptide myristate binding site, said polypeptide consisting of SEQ ID NO.:
- 1, a pharmaceutically acceptable carrier, and an immune stimulant wherein said immune stimulant comprises cobra venom factor and wherein said composition is capable of inducing a Th1 immune response to HIV-1.
Dependencies are inferred from the claim text.